Download PDF
Der Nuklearmediziner 2012; 35(03): 186-191
DOI: 10.1055/s-0032-1321794
Diagnostik und Therapie von Skeletterkrankungen – Update 2012
© Georg Thieme Verlag KG Stuttgart · New York

Therapie mit offenen Radionukliden bei multilokulärer Skelettmetastasierung

Radionuclide Therapy of Multilocular Bone Metastases
M. Fischer
1   Praxis für Radiologie, Nuklearmedizin und Strahlentherapie, Kassel
,
W. U. Kampen
2   Nuklearmedizin Spitalerhof, Hamburg
› Author Affiliations
Further Information

Publication History

Publication Date:
11 September 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die nuklearmedizinische palliative Schmerztherapie stellt eine nebenwirkungsarme, ergänzende Behandlungsoption im Gesamtspektrum der Schmerztherapie bei Patienten mit einer multilokulär osteoblastischen Metastasierung vieler Primärtumoren dar. Sie zeichnet sich durch einen raschen Einsatz der Schmerzlinderung und durch lang anhaltende Wirkung aus. Vorläufige Berechnungen weisen auf eine günstige Kosten-Nutzen-Relation hin. Durch die nuklearmedizinische palliative Schmerztherapie bessert sich bei Patienten mit metastasiertem Mamma- oder Prostatakarzinom die Schmerzsymptomatik in 70–80%, bei anderen Primärtumoren weniger häufig [7] [10]. Völlig schmerzfrei werden nur wenige Patienten. Eine medikamentöse Basistherapie ist bei den meisten Tumorpatienten weiterhin erforderlich. Insgesamt zeichnet sich die Therapie durch eine hohe Akzeptanz bei den Patienten aus, da es sich bei der Verwendung von 89Strontium oder 153Samarium um eine einmalige intravenöse Applikation handelt. Aktuelle Studien zum kombinierten Einsatz von Radionukliden und Chemotherapie bzw. die klinischen Daten der Anwendung von 223Radium belegen weitere Entwicklungsmöglichkeiten der systemischen Radionuklidtherapie von einer rein palliativen Behandlung hin zu tumoriziden Effekten mit signifikanter Lebensverlängerung der betroffenen Patienten.

Abstract

Pain palliation therapy using radionulides is a safe, additive therapeutic procedure in the spectrum of effective treatment in patients with multilocular mainly osteoblastic skeletal metastases from different primaries. The radionulide therapy is characterized by fast pain palliation and long-term symptom benefit in 70–80% of patients suffering from breast or prostate cancer. Lower response rates are observed in other primaries. Only few patients are becoming totally pain free, most patients have to continue basal therapy with pain medication.

The single intraveneous administration is well tolerated and accepted by most patients. Recent studies administering combination therapy of radionuclides and chemotherapy show promising effects on tumoricity. Also preliminary results of trials using 223Radium, an alpha emitter show good pain symptom control and significantly prolonged survival.

Schlüsselwörter

Knochenmetastasen - Schmerztherapie - 153Samarium EDTMP - 89Strontium - 223Radium

Key words

bone metastases - pain treatment - 153Samarium EDTMP - 89Strontium - 223Radium
 

  • Literatur

  • 1 Brucher M. A chronology of nuclear medicine. St. Louis: Heritage Publications; 1990
    Google Scholar
  • 2 Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006; 25: 4663-4674
    CrossrefPubMedGoogle Scholar
  • 3 Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998; 77: 336-340
    CrossrefPubMedGoogle Scholar
  • 4 Coleman RE. Metastatic bone disease: clinical features pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176
    CrossrefPubMedGoogle Scholar
  • 5 Collins C, Eary JF, Donaldson G et al. Samarium-153 EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34: 1839-1844
    PubMedGoogle Scholar
  • 6 De Puy V, Anstrom KJ, Castel LD et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007; 15: 869-876
    CrossrefPubMedGoogle Scholar
  • 7 Elgazzar AH, Maxon HR. Radioisotope therapy of cancer related bone pain. In: Limouris GS, Shukla SK. (eds.). Radionuclides for therapy. Athen: Mediterra Publishers; 1993: 111-116
    Google Scholar
  • 8 Fischer M. Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 1999; 38: 270-272
    PubMedGoogle Scholar
  • 9 Fischer M, Kampen WU. Radionuclide therapy of bone metastases. Breast Care 2012; 7: 100-107
    CrossrefPubMedGoogle Scholar
  • 10 Fuster D, Herranz R, Vidal-Sicart S et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 2000; 21: 623-626
    CrossrefPubMedGoogle Scholar
  • 11 Geldof AA, de Rooij L, Versteegh RT et al. Combination 186-Re-HEDP and cistplatin supraadditive treatment effects in prostate cancer cells. J Nucl med 1999; 40: 667-671
    PubMedGoogle Scholar
  • 12 Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogenety and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892
    CrossrefPubMedGoogle Scholar
  • 13 Inoue T, Segawa T, Kamba T et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009; 73: 1104-1109
    CrossrefPubMedGoogle Scholar
  • 14 Kampen WU, Czech N, Fischer M. Nuklearmedizinische Schmerztherapie. In: Baron R, Koppert W, Strumpf M, Willweber-Strumpf A. Hrsg Praktische Schmerztherapie. Springer; Heidelberg: 2007: 207-215
    CrossrefGoogle Scholar
  • 15 Krishnamurthy GT, Krishnamurthy S. Invited commentary: Radionuclides for metastatic bone pain palliation: a need for rational re-evaluattion in the new millennium. J Nucl Med 2000; 41: 688-691
    PubMedGoogle Scholar
  • 16 Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89 Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007; 28: 623-630
    CrossrefPubMedGoogle Scholar
  • 17 Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000; 21 (03) 379-385
    CrossrefPubMedGoogle Scholar
  • 18 Marcus CS, Saeed S, Mlikotic A et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153-EDTMP. Clin Nucl Med 2002; 27: 427-430
    CrossrefPubMedGoogle Scholar
  • 19 McEwan AJB. Palliation of bone pain. In: Murray IPC, Ell PJ. Hrsg Nuclear medicine in Clinical Diagnosis and Treatment. Churchill Livingston; Edinburgh: 1994: 877-892
    Google Scholar
  • 20 Mend Y, Bushnell DL, Williams RD et al. Efficacy and safety of repeated Samarium-153 Lexidrnam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med 2000; 25: 698-700
    CrossrefPubMedGoogle Scholar
  • 21 Minutoli F, Herberg A, Spadaro P et al. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging 2006; 50: 355-362
    PubMedGoogle Scholar
  • 22 Nilsson S, Parker C, Tyrell C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-594
    CrossrefPubMedGoogle Scholar
  • 23 Nørgaard M, Jensen AØ, Jacobsen JB et al. Skeletal related events, bone metastases and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162-167
    CrossrefPubMedGoogle Scholar
  • 24 Paes FM, Serafini AN. Systemic metabolic raqdiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40: 89-104
    PubMedGoogle Scholar
  • 25 Parker C et al. Role of Radium-223 in the treatment of advanced prostate cancer. Poster Presentation ECCO ESMO 2011
    PubMedGoogle Scholar
  • 26 Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Pub Pharmacol 1942; 2: 117-149
    PubMedGoogle Scholar
  • 27 Porter AT, McEwan AJB, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Phys 1993; 25: 805-813
    CrossrefPubMedGoogle Scholar
  • 28 Quattrocchino CC, Piciucchi S, Sammarra M et al. Bone metastases in breast cancer: higher prevalence of osteoblastic lesions. Radiol Med 2007; 112: 1049-1059
    CrossrefPubMedGoogle Scholar
  • 29 Resche I, Chatal JF, Pecking A et al. A dose controlled study of Sm-153 ethylenediaminetetramethylenephosphate in the treatment of patients with painful metastases. Eur J Cancer 1997; 33: 1583-1591
    CrossrefPubMedGoogle Scholar
  • 30 Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev 2012; http://dx.doi.org/10.1016/j.ctrv2012.03.006
    PubMedGoogle Scholar
  • 31 Sciuto R, Festa A, Rea S et al. Effects of low-dose cisplatin on 89-Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43: 79-86
    PubMedGoogle Scholar
  • 32 Suomine MI, Rissanen JK, Käkönen R et al. Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo. Am Ass Cancer Research Annual Meeting 2011; abstr. 2664
    PubMedGoogle Scholar
  • 33 Tu SM, Delpass ES, Jones D et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgen independent prostate cancer. Urol Oncol 1997; 2: 191-197
    PubMedGoogle Scholar
  • 34 World Health Organisation . Cancer pain relief and palliative care. WHO Technical Report Series 1990; 804: 7-73
    PubMedGoogle Scholar